Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic Malignancies

April 15th 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

April 15th 2024

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

April 15th 2024

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

MRD-Negative CR Separates Ponatinib From the Rest in Newly Diagnosed, Ph+ ALL

April 15th 2024

Ibrahim Aldoss, MD, discusses the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.

Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL

April 15th 2024

Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.

Glofitamab Plus Chemotherapy Meets OS End Point in R/R DLBCL

April 15th 2024

Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

NICE Recommends Tisagenlecleucel for Pediatric R/R B-ALL

April 11th 2024

The National Institute for Health and Care Excellence has recommended the use of tisagenlecleucel in pediatric B-cell acute lymphoblastic leukemia.

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

April 10th 2024

The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

April 10th 2024

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

FDA Grants Fast Track Designation to Tamibarotene/Azacitidine/Venetoclax for RARA-Overexpressed AML

April 10th 2024

Tamibarotene plus azacitidine and venetoclax has received FDA fast track designation for newly diagnosed, unfit, RARA-overexpressed AML.

Emerging Treatments for Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.

Individualizing Therapy Goals for Patients With Myelofibrosis

April 10th 2024

Andrew Kuykendall, MD, emphasizes the importance of individualizing therapy for patients with myelofibrosis, focusing on improving quality of life and addressing specific issues like anemia and spleen volume, with the understanding that these treatments are palliative and goals should be revisited regularly.

Dr Patel-Donnelly on Factors Influencing Consolidation Therapy in Hematologic Malignancies

April 8th 2024

Dipti Patel-Donnelly, MD, discusses key factors to consider when selecting consolidation therapies in high-risk hematologic malignancies.

FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

April 8th 2024

The FDA has accepted for review the new drug application for SH-201 for the treatment of patients with certain forms of leukemia and other cancers.

Sotomayor Elucidates Updates Including ADC and Bispecific Antibody Combinations in Hematology

April 6th 2024

Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.

Dr. Jasmine Zain: Challenges in T-Cell Lymphoma Treatment

April 5th 2024

Jasmine Zain, MD, director of the T-cell Lymphoma Program, professor of hematology and hematopoietic stem cell transplantation, of City of Hope National Medical Center, discusses the challenges of treatment for patients with T-cell lymphoma.

Dr Ip on the Implications of NGS Plus Machine Learning for Diagnosing Hematologic Malignancies

April 4th 2024

Andrew Ip, MD, discusses the implications of using next-generation sequencing alongside machine learning in the diagnosis of hematologic malignancies.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Targeted Therapies Are Finding Their Footing in Hematologic Malignancies

April 4th 2024

Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.